Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/278359
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection |
Autor: | Torres, Ignacio; Giménez, Estela; Albert, Eliseo; Zulaica, Joao CSIC ORCID; Álvarez-Rodríguez, Beatriz CSIC ORCID; Burgos, Javier S.; Peiró, Salvador; Limón, Ramón; Vanaclocha, Hermelinda; Rodado, Celia; Botija, Pilar; Sifre, Amelia; Tur, Borja; Andrés Lozano, Rosa; Orosa, Iria; Vicente-Ruiz, M. Ángeles; Carrión, Ramón J.; Clari, María Á.; Sánchez-Payá, José; Díez-Domingo, Javier; Comas, Iñaki CSIC ORCID ; González-Candelas, Fernando CSIC ORCID; Geller, Ron CSIC ORCID ; Navarro, David; Valencian Vaccine Research Program (ProVaVac) study group | Palabras clave: | Comirnaty® COVID-19 vaccine SARS-CoV-2 Omicron variant Anti-spike antibodies Breakthrough infection Neutralizing antibodies Nursing home residents spike-reactive T cells |
Fecha de publicación: | sep-2022 | Editor: | Wiley-Blackwell | Citación: | Journal of Medical Virology 94(9):4216-4223 (2022) | Resumen: | We investigated whether peripheral blood levels of SARS-CoV-2 Spike (S) receptor binding domain antibodies (anti-RBD), neutralizing antibodies (NtAb) targeting Omicron S, and S-reactive-interferon (IFN)-γ-producing CD4+ and CD8+ T cells measured after a homologous booster dose (3D) with the Comirnaty® vaccine was associated with the likelihood of subsequent breakthrough infections due to the Omicron variant. An observational study including 146 nursing home residents (median age, 80 years; range, 66-99; 109 female) evaluated for an immunological response after 3D (at a median of 16 days). Anti-RBD total antibodies were measured by chemiluminescent immunoassay. NtAb were quantified by an Omicron S pseudotyped virus neutralization assay. SARS-CoV-2-S specific-IFNγ-producing CD4+ and CD8+ T cells were enumerated by whole-blood flow cytometry for intracellular cytokine staining. In total, 33/146 participants contracted breakthrough Omicron infection (symptomatic in 30/33) within 4 months after 3D. Anti-RBD antibody levels were comparable in infected and uninfected participants (21 123 vs. 24 723 BAU/ml; p = 0.34). Likewise, NtAb titers (reciprocal IC50 titer, 157 vs. 95; p = 0.32) and frequency of virus-reactive CD4+ (p = 0.82) and CD8+ (p = 0.91) T cells were similar across participants in both groups. anti-RBD antibody levels and NtAb titers estimated at around the time of infection were also comparable (3445 vs. 4345 BAU/ml; p = 0.59 and 188.5 vs. 88.9; p = 0.70, respectively). Having detectable NtAb against Omicron or SARS-CoV-2-S-reactive-IFNγ-producing CD4+ or CD8+ T cells after 3D was not correlated with increased protection from breakthrough infection (OR, 1.50; p = 0.54; OR, 0.0; p = 0.99 and OR 3.70; p = 0.23, respectively). None of the immune parameters evaluated herein, including NtAb titers against the Omicron variant, may reliably predict at the individual level the risk of contracting COVID-19 due to the Omicron variant in nursing home residents. | Versión del editor: | https://dx.doi.org/10.1002/jmv.27867 | URI: | http://hdl.handle.net/10261/278359 | DOI: | 10.1002/jmv.27867 | ISSN: | 0146-6615 | E-ISSN: | 1096-9071 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (IBV) Artículos (I2SysBio) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
6
checked on 12-abr-2024
SCOPUSTM
Citations
11
checked on 09-may-2024
WEB OF SCIENCETM
Citations
8
checked on 23-feb-2024
Page view(s)
65
checked on 16-may-2024
Download(s)
20
checked on 16-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.